BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 21403648)

  • 1. A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function.
    Vallet S; Pozzi S; Patel K; Vaghela N; Fulciniti MT; Veiby P; Hideshima T; Santo L; Cirstea D; Scadden DT; Anderson KC; Raje N
    Leukemia; 2011 Jul; 25(7):1174-81. PubMed ID: 21403648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
    Oba Y; Lee JW; Ehrlich LA; Chung HY; Jelinek DF; Callander NS; Horuk R; Choi SJ; Roodman GD
    Exp Hematol; 2005 Mar; 33(3):272-8. PubMed ID: 15730850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.
    Menu E; De Leenheer E; De Raeve H; Coulton L; Imanishi T; Miyashita K; Van Valckenborgh E; Van Riet I; Van Camp B; Horuk R; Croucher P; Vanderkerken K
    Clin Exp Metastasis; 2006; 23(5-6):291-300. PubMed ID: 17086356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of CCL3 and CCR1 in bone remodeling induced by mechanical loading during orthodontic tooth movement in mice.
    Taddei SR; Queiroz-Junior CM; Moura AP; Andrade I; Garlet GP; Proudfoot AE; Teixeira MM; da Silva TA
    Bone; 2013 Jan; 52(1):259-67. PubMed ID: 23059626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma.
    Abe M; Hiura K; Wilde J; Moriyama K; Hashimoto T; Ozaki S; Wakatsuki S; Kosaka M; Kido S; Inoue D; Matsumoto T
    Blood; 2002 Sep; 100(6):2195-202. PubMed ID: 12200385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.
    Dairaghi DJ; Oyajobi BO; Gupta A; McCluskey B; Miao S; Powers JP; Seitz LC; Wang Y; Zeng Y; Zhang P; Schall TJ; Jaen JC
    Blood; 2012 Aug; 120(7):1449-57. PubMed ID: 22618707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease.
    Fu R; Liu H; Zhao S; Wang Y; Li L; Gao S; Ruan E; Wang G; Wang H; Song J; Shao Z
    Cancer Cell Int; 2014; 14(1):132. PubMed ID: 25520585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways.
    Tsubaki M; Kato C; Manno M; Ogaki M; Satou T; Itoh T; Kusunoki T; Tanimori Y; Fujiwara K; Matsuoka H; Nishida S
    Mol Cell Biochem; 2007 Oct; 304(1-2):53-60. PubMed ID: 17549607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow expression of CCL3 is not correlated with the extent of lytic bone lesions.
    Cohen Y; Gutwein O; Garach-Jehoshua O; Bar-Haim A; Kornberg A
    Acta Haematol; 2014; 132(2):129-33. PubMed ID: 24556596
    [No Abstract]   [Full Text] [Related]  

  • 11. [Mechanisms for formation of myeloma bone disease].
    Yata K; Abe M; Matsumoto T
    Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model.
    Kassen D; Lath D; Lach A; Evans H; Chantry A; Rabin N; Croucher P; Yong KL
    Br J Haematol; 2016 Jan; 172(1):64-79. PubMed ID: 26767468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand.
    Han JH; Choi SJ; Kurihara N; Koide M; Oba Y; Roodman GD
    Blood; 2001 Jun; 97(11):3349-53. PubMed ID: 11369623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the bone marrow microenvironment in multiple myeloma.
    Roodman GD
    J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stromal derived factor-1 regulates bone morphogenetic protein 2-induced osteogenic differentiation of primary mesenchymal stem cells.
    Hosogane N; Huang Z; Rawlins BA; Liu X; Boachie-Adjei O; Boskey AL; Zhu W
    Int J Biochem Cell Biol; 2010 Jul; 42(7):1132-41. PubMed ID: 20362069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.
    Oyajobi BO; Franchin G; Williams PJ; Pulkrabek D; Gupta A; Munoz S; Grubbs B; Zhao M; Chen D; Sherry B; Mundy GR
    Blood; 2003 Jul; 102(1):311-9. PubMed ID: 12649140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.
    Giuliani N; Lisignoli G; Colla S; Lazzaretti M; Storti P; Mancini C; Bonomini S; Manferdini C; Codeluppi K; Facchini A; Rizzoli V
    Cancer Res; 2008 Aug; 68(16):6840-50. PubMed ID: 18703490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCR1 as a target for multiple myeloma.
    Vallet S; Anderson KC
    Expert Opin Ther Targets; 2011 Sep; 15(9):1037-47. PubMed ID: 21609295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process.
    Wu Y; Li YY; Matsushima K; Baba T; Mukaida N
    J Immunol; 2008 Nov; 181(9):6384-93. PubMed ID: 18941229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of SLC41A1 magnesium transporter promotes mineralization and attenuates magnesium inhibition during osteogenesis of mesenchymal stromal cells.
    Tsao YT; Shih YY; Liu YA; Liu YS; Lee OK
    Stem Cell Res Ther; 2017 Feb; 8(1):39. PubMed ID: 28222767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.